Portage Biotech Resumes PORT-6 Phase 1b Trial, Advancing Dose Escalation In Immuno-Oncology Research

Portage Biotech Inc., a clinical-stage immuno-oncology company, has resumed patient enrollment in the fourth and final cohort of the dose escalation phase for PORT-6, a selective A2A antagonist, as part of its ADPORT-601 Phase 1b clinical trial. The trial had been temporarily paused due to funding limitations, but its continuation reflects positive findings from earlier study phases. This marks a significant step in evaluating PORT-6’s safety and therapeutic potential.

“Our review of the preliminary data reinforces our confidence in PORT-6 and supports the decision to complete dose escalation. We remain encouraged by the trial’s progress and potential and look forward to sharing further clinical updates later this year,” said Alexander Pickett, Chief Executive Officer of Portage Biotech. The completion of the PORT-6 arm will stimulate Portage to decide if they should execute the PORT-7 segment that tests a selective A2B antagonist while exploring various combination treatment possibilities. Portage Biotech resumed with final dose-escalation research, indicating its faith in PORT-6 potential as a developmental candidate.